Harvard Bioscience, Inc. · NASDAQ:HBIO

Harvard Bioscience — Investor Presentation (August 2006)

27 slides from Harvard Bioscience's investor presentation, August 2006

  1. Slide 1: Tools to Advance Life Science Research

    Slide 1: Tools to Advance Life Science Research

    Tools to Advance Life Science Research NASDAQ HBIO August 2006 Copyright © Harvard Bioscience 2006

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the federal securities laws. You can identify these statements by our use of the words “guidance,” “expects,” “plans,” “estimates,” “projects,” “intends,” “believes” and similar expressions that do not

  3. Slide 3: Use of Non-GAAP Information

    Slide 3: Use of Non-GAAP Information

    Use of Non-GAAP Information In this presentation, we have included non-GAAP financial information including adjusted operating income and adjusted net income per diluted share. We believe that this non-GAAP financial information provides investors with an enhanced understanding of the underlying ope

  4. Slide 4: Investment Highlights

    Slide 4: Investment Highlights

    Investment Highlights • Tools to Advance Life Science Research • Strong Track Record of Growth and Profitability • Currently Divesting Volatile Capital Equipment Business • Currently Trading at a Discount to Comparable Companies • Experienced Management Team • Commitment to Stockholder Value Creatio

  5. Slide 5: Overview

    Slide 5: Overview

    Overview • Financial Performance Overview • Valuation • Business Strategy • Growth Model • Management Team • Commitment to Stockholder Value Copyright © Harvard Bioscience 2006 Tools to Advance Life Science Research

  6. Slide 6: Financial Overview – Strong Revenue Growth

    Slide 6: Financial Overview – Strong Revenue Growth

    Financial Overview – Strong Revenue Growth $80.0 Revenue from Continuing CAGR $70.0 Operations $64.7 $67.4 25% $60.0 $52.0 $50.0 $47.0 (in millions) $40.0 IPO $38.1 $30.6 $30.0 $26.2 $20.0 $11.5 $12.1 $10.0 $- 1997 1998 1999 2000 2001 2002 2003 2004 2005 Copyright © Harvard Bioscience 2006 Tools to

  7. Slide 7: Financial Overview – Strong Profitability

    Slide 7: Financial Overview – Strong Profitability

    Financial Overview – Strong Profitability $12.0 Non-GAAP Adjusted Operating Income $10.3 CAGR $10.0 from Continuing Operations $9.9 21% $8.9 $8.0 $7.8 $6.9 (in millions) $6.0 $4.8 $4.8 $4.0 $2.4 $2.1 $2.0 $- 1997 1998 1999 2000 2001 2002 2003 2004 2005 Note: See reconciliation of US GAAP operating i

  8. Slide 8: Financial Overview – Strong Diluted EPS Growth

    Slide 8: Financial Overview – Strong Diluted EPS Growth

    Financial Overview – Strong Diluted EPS Growth Non-GAAP Adjusted Diluted EPS from Continuing Operations $0.20 $0.19 $0.19 $0.19 $0.19 CAGR 13% $0.18 $0.17 $0.17 $0.16 $0.15 $0.14 $0.12 $0.10 $0.10 $0.08 $0.07 $0.06 $0.04 $0.02 $- 1997 1998 1999 2000 2001 2002 2003 2004 2005 Note: See reconciliation

  9. Slide 9: Financial Overview – 2005 (Continuing Operations)

    Slide 9: Financial Overview – 2005 (Continuing Operations)

    Financial Overview – 2005 (Continuing Operations) Revenue Org. Rev. Growth Adj. Dil. EPS Q1 $16.1m (0)%* $0.04 Q2 $16.3m 4% $0.04 Q3 $17.2m 5% $0.05 Q4 $17.8m 7% $0.06 2005 $67.4m 4% $0.19 Investments made in late 2004 and early 2005 started paying off. * Discontinued Operations accounting for the C

  10. Slide 10: Financial Overview – 2006 Actual and Guidance

    Slide 10: Financial Overview – 2006 Actual and Guidance

    Financial Overview – 2006 Actual and Guidance (Continuing Operations) Revenue Adj. Dil. EPS Q1(Actual) $17.4m $0.06 Q2 (Actual) $18.2m $0.07 2006 (Guidance) $72m - $73m $0.24 - $0.25 Beat own estimates for revenue and adjusted diluted EPS and analysts estimates two quarters in a row Raised 2006 guid

  11. Slide 11: HBIO Comparables Valuation

    Slide 11: HBIO Comparables Valuation

    HBIO Comparables Valuation HBIO trades at a substantial discount to comps: Price to PE Ratio PE Ratio Sales 2006 2007 Ratio Molecular Devices 3.0 28 24 Caliper Life Science 2.3 N/A N/A Harvard Bioscience 2.0 22* 20 Source: Yahoo Finance, August 28, 2006 * Yahoo’s 2006 EPS estimate is $0.19, at our g

  12. Slide 12: HBIO Continuing Operations

    Slide 12: HBIO Continuing Operations

    HBIO Continuing Operations Established in 1901 at 100 years, 1000 pages, Harvard Medical School 11,000 items & a web site The name Harvard is used under a license agreement between Harvard Bioscience and Harvard University Copyright © Harvard Bioscience 2006 Tools to Advance Life Science Research

  13. Slide 13: Physiology Products

    Slide 13: Physiology Products

    Physiology Products Syringe Pumps – Animal Ventilators – Cell & Tissue Incubators – clear market leader clear market leader market leader Sample Prep – great technology Organ Systems – clear with big ideas Electroporation – market leader strong #2 with new technology Market shares are management est

  14. Slide 14: Molecular Biology Products

    Slide 14: Molecular Biology Products

    Molecular Biology Products Plate Readers – small share with big plans Spectrophotometers – #2 in life science Hoefer 1D Electrophoresis Tanks - #1 or #2 Amino Acid Analyzer – clear market leader Market shares are management estimates and Copyright © Harvard Bioscience 2006 have not been independentl

  15. Slide 15: Established Distribution Channels

    Slide 15: Established Distribution Channels

    Established Distribution Channels Catalog and Website - Harvard Apparatus Catalog - Over 100 years, 1,000 pages, 10,000 items - Hoefer Catalog (electrophoresis) - New catalog Q1 2006 Major Distributors - GE Healthcare (formerly Amersham Bioscience) - Over 20 year relationship - Fisher Scientific, VW

  16. Slide 16: Established Customer Base

    Slide 16: Established Customer Base

    Established Customer Base • 35/35 Top Pharmaceutical Companies • 50/50 Top Research Universities • 50,000 Qualified End-Users in Our Database Copyright © Harvard Bioscience 2006 Tools to Advance Life Science Research

  17. Slide 17: Business Strategy

    Slide 17: Business Strategy

    Business Strategy Our strategy is to have a broad range of highly specialized but relatively inexpensive products that have strong positions in niche markets in life science research: - We believe that having a broad product offering reduces the risk of being dependent on a single technology; - We b

  18. Slide 18: Growth Strategy

    Slide 18: Growth Strategy

    Growth Strategy • Organic growth in mature markets driven by expanding distribution channels and product offerings, plus • Tuck-under acquisitions of related product lines. • We have made 17 acquisitions in the Apparatus business since March 1996. Copyright © Harvard Bioscience 2006 Tools to Advance

  19. Slide 19: Growth Model

    Slide 19: Growth Model

    Growth Model Revenue Growth Projected Organic 4-6% Tuck-under acquisitions* 10-15% Total revenue growth 14-21% Operating Income Growth 15-20% Actual 1997 to 2005 revenue growth was 25% annually and operating income growth was 21% annually * Note: We believe we can finance this level of tuck-under ac

  20. Slide 20: Experienced Management Team

    Slide 20: Experienced Management Team

    Experienced Management Team • 60+ years of Relevant Experience • Many Licensing Deals and New Product Launches • 20 Acquisitions at HBIO Title Background Chane Graziano CEO Waters, ATI Orion David Green President Monitor, Unilever Sue Luscinski COO Harvard Bioscience Bryce Chicoyne CFO Apogent, E&Y

  21. Slide 21: Commitment to Stockholder Value

    Slide 21: Commitment to Stockholder Value

    Commitment to Stockholder Value • Management team collectively holds approximately 20% of shares • Management owns an additional approximately 5% in options most at $7-8 per share • We believe tuck-under growth strategy can be financed with current cash available, cash flow from operations and proce

  22. Slide 22: Investment Highlights

    Slide 22: Investment Highlights

    Investment Highlights • Tools to Advance Life Science Research • Strong Track Record of Growth and Profitability • Currently Divesting Volatile Capital Equipment Business • Currently Trading at a Discount to Comparable Companies • Experienced Management Team • Commitment to Stockholder Value Creatio

  23. Slide 23: Tools to Advance Life Science Research

    Slide 23: Tools to Advance Life Science Research

    Tools to Advance Life Science Research NASDAQ HBIO Copyright © Harvard Bioscience 2006

  24. Slide 24: Appendix A

    Slide 24: Appendix A

    Appendix A For the years ended December 31, 1997 1998 1999 2000 (IPO) 2001 2002 2003 2004 2005 Revenues $ 11,464 $ 12,154 $ 26,178 $ 30,575 $ 38,088 $ 47,009 $ 52,024 $ 64,745 $ 67,431 For the years ended December 31, Reconciliation of GAAP to Non-GAAP Adjusted: 1997 1998 1999 2000 2001 2002 2003 20

  25. Slide 25: Appendix B

    Slide 25: Appendix B

    Appendix B HARVARD BIOSCIENCE, INC. Reconciliation of Changes In Total Revenue Compared to the Same Period of the Prior Year (Continuing Operations) (unaudited) For the six For the three months ended months ended March 31, June 30, September 30, December 30, March 31, June 30, June 30, 2005 2005 200

  26. Slide 26: Appendix C

    Slide 26: Appendix C

    Appendix C For the quarter ended March 31, 2005 June 30, 2005 September 30, 2005 December 31, 2005 Revenues $ 16,135 $ 16,277 $ 17,179 $ 17,840 For the quarter ended Reconciliation of GAAP to Non-GAAP Adjusted: March 31, 2005 June 30, 2005 September 30, 2005 December 31, 2005 US GAAP operating incom

  27. Slide 27: Appendix D

    Slide 27: Appendix D

    Appendix D Reconciliation of Guidance for US GAAP Continuing Operations Income per Diluted Share to Adjusted Non-GAAP Continuing Operations Income per Diluted Share (unaudited) Three Months Ended Year Ended September 30, 2006 December 31, 2006 Low Estimate High Estimate Low Estimate High Estimate No

Source: Internet Archive copy of harvardbioscience.com

More decks from Harvard Bioscience, Inc.

All 44 Harvard Bioscience decks